CPT 93886, in plain terms, covers Complete transcranial Doppler study of the intracranial arteries. CPT 93886 is referenced in 3 tracked payer policy changes from Medicare/CMS - LCD and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 93886 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Official descriptor: CPT 93886 on AAPC
CGS's LCD L34045 (Non-Invasive Vascular Studies), revised with an effective date of 11/5/2026, expands coverage to include arterial fibromuscular dysplasia (FMD) for non-invasive vascular studies, based on new literature and societal input supporting non-invasive testing for this condition. The revision is described as a coverage expansion rather than a restriction, with all other existing indications and limitations carried over from the prior version.
Aetna considers in-office and in-hospital antepartum fetal surveillance with non-stress tests, contraction stress tests, biophysical profiles, modified biophysical profiles, and umbilical artery and middle cerebral artery Doppler velocimetry medically necessary when the criteria in this policy are met. For most pregnancies at increased risk of stillbirth due to utero-placental insufficiency, testing is considered appropriate beginning at 32 to 34 weeks of gestation, and testing is medically necessary beginning at 26 weeks for pregnancies with multiple or particularly worrisome high-risk conditions. Repeat testing is medically necessary until delivery while the condition that prompted testing persists, and remote non-stress testing, uterine artery Doppler for risk assessment or screening, and all other indications not listed as medically necessary are considered experimental, investigational or unproven.
Aetna considers transcranial Doppler ultrasonography medically necessary for indications including assessing collateral blood flow and embolization during carotid endarterectomy, evaluating persons with suspected brain death, detecting microemboli after stroke or transient ischemic attack, evaluating giant cell arteritis, and assessing stroke risk in children aged 2 to 16 years with sickle cell anemia. Aetna considers it experimental, investigational, or unproven for all other indications, including screening for carotid artery stenosis in asymptomatic adults, managing traumatic brain injury, migraine headaches, epilepsy, and evaluating adults with sickle cell anemia. The covered CPT codes are 93886, 93888, 93890, 93892, 93893, 93896, 93897 and 93898 when selection criteria are met.
Watch 93886
Get one email when a payer policy names 93886, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.